Sema4
Sema4 Reports 56 Percent Increase in Q2 Revenues
For the quarter ended June 30, the Stamford, Connecticut-based firm booked $46.9 million in revenues, up from $30.1 million in the year-ago quarter.
The genetic testing and health intelligence firm will start trading on the Nasdaq Global Select Market on Friday under the ticker symbols SMFR and SMFRW.
Experts cautioned, however, that firms will need a broader portfolio than just COVID-19 testing for sustainability in the public markets.
In Brief This Week: BioReference Laboratories, Tecan Group, Personal Genome Diagnostics, Sema4
News items for the in vitro diagnostics industry for the week of June 21, 2021.
Sema4 to Go Public Through Merger With Special Purpose Acquisition Company
The deal, which values Sema4 at approximately $2 billion and will deliver up to $793 million in gross proceeds, is expected to close during the second quarter.
Jul 29, 2020
Sema4 Raises $121M in Series C Financing Round
Aug 29, 2019